Decision Diagnostics Rejects Settlement Offers From J&J/Lifescan, Company's Prosecutions of Court Bond and Anti-Trust Actions Now Move On

LOS ANGELES, CA--(Marketwired - Mar 4, 2015) - Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip™ 50, the FDA cleared Green Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, today announced that despite repeated refusal of Lifescan's mediation overtures, the company was ordered to attend a mandatory, court-directed mediation on January 29, 2015. Following two separate days of these compulsory discussions at the Federal District Court for Northern California (San Francisco), which concluded on February 23, the company has again rejected Lifescan's settlement offers.

Keith Berman, Principal Executive Officer and CFO stated: "As we have repeatedly stated during this lengthy process, J&J/Lifescan will not be readily released from its legal and financial obligations stemming from its onerous actions against our product and company. A modest level of compensation will not rectify the considerable damages that they have inflicted. Our positions will be vindicated, our product fully restored and our shareholders rewarded for their patience. No company, regardless of their size, wealth or power, can willfully ignore all legal and ethical business practices. We will prevail and will be awarded appropriate reparations for our sustained damages."

The company, more importantly, is announcing that the preparation for an expected explosion of product demand following legal victory has already begun. Solicitations for interview and quotation have been circulated to various internationally certified and FDA approved manufacturers for the contract manufacture of GenStrip™ 50. The time frame for tooling creation, first article part delivery and full product production is expected to fall within a five to seven month timeframe, following the final selection of an international contract manufacturer. Concurrent to the fulfillment of supplemental GenStrip™ 50 manufacturing, that selected manufacturer will simultaneously be charged with the completion of a new product that has been under internal development for nearly a year. Several of these manufacturing candidates are currently manufacturing second generation, FDA cleared, embryonic versions of the company's (3^rd generation) product concept.